Effects of DRD1 polymorphisms on response to clozapine in resistant schizophrenic patients
10.3760/cma.j.issn.1674-6554.2012.03.016
- VernacularTitle:难治性精神分裂症患者多巴胺D1受体基因多态性对氯氮平疗效的影响
- Author:
Guojun XIE
;
Jiaqiang CHEN
;
Xuesong LI
;
Yan PENG
;
Xiaojuan WANG
- Publication Type:Journal Article
- Keywords:
Resistant schizophrenia;
Dopamine receptor D1;
Polymorphisms;
Clozapine
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2012;21(3):241-243
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of DRD1 rs265981,rs4532,rs686 and rs265976 polymorphisms on response to clozapine in resistant schizophrenic patients.Methods DRD1 genotype was determined by SNaPshot SNP technique for 154 patients with resistant schizophrenia.Clinical symptoms were evaluated by Positive and Negative Syndrome Scale (PANSS),and the responder was defined as a reduction of 50％ on PANSS score from baseline after the patients were administered orally clozapine for 8 weeks.Results The frequencies of rs265981 genotypes,alleles and rs265976 genotypes had significant differences between clozapine responder group (88 cases) and nonresponder group(66 cases) in total clinical efficacy ( x2 =10.215,P =0.004 ; x2 =4.082,P =0.041 ; x2 =14.083,P =0.007 ).The frequencies of rs265976 genotypes had significant differences between clozapine response (58 cases) and nonresponse (96 cases) to negative symptom ( x2 =9.805,P =0.046).Conclusion The polymorphisms of DRD1 gene rs265981 and rs265976 may relate with clinical response to clozapine in resistant schizophrenias.rs265981 T/T,allele T and rs265976 genotype A/A are likely to be predictive factors to the improvement of total clozapine therapeutic effects.rs265976 genotype A/A are likely to be predictive factors of negative symptom with treatment of clozapine.
